Lanean...
SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
BACKGROUND: Sodium glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of heart failure and new data show they can prevent atrial fibrillation (AF). We examined the association between SGLT2i and AF in the Food and Drug Administration adverse event reporting system (FAERS). METHODS: We mined...
Gorde:
| Argitaratua izan da: | Cardiovasc Diabetol |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7879696/ https://ncbi.nlm.nih.gov/pubmed/33573667 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-021-01243-4 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|